SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Chiasma, Inc. (NASDAQ: CHMA)

NEW YORK, April 19, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Chiasma, Inc. ("Chiasma" or the "Company") (NASDAQ: CHMA). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at [email protected] or 212-697-6484.

This investigation concerns whether Chiasma and certain of its officers and/or directors have violated the Federal Securities Laws under the Securities Exchange Act of 1934 (the "Exchange Act"). 

Chiasma is a biopharmaceutical company focused on developing and commercializing orphan medications to better meet the needs of patients and healthcare professionals.

This investigation seeks to determine whether Chiasma's filings with the U.S. Securities and Exchange Commission in connection with its July 2015 initial public stock offering (the "IPO") contained falsified statements or omitted to state important facts in regards to Chiasma's business and financial prospects.

In July 2015, Chiasma offered over 6,300,000 of its common stock at $16.00 per share in connection with its IPO. Following the news of the U.S. Food and Drug Administration's rejection of the Chiasma's drug to treat acromegaly, a rare disease of the pituitary gland, Chiasma shares dropped and were trading below $4.50 pre-market on April 18, 2016.

If you are aware of any facts relating to this investigation, or purchased shares of Chiasma, you can assist this investigation by visiting the firm's website: http://www.bgandg.com/#!chma/ts6n9. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected].  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC

Related Links

http://www.bgandg.com